These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 16300168)
21. The interaction of diltiazem with lovastatin and pravastatin. Azie NE; Brater DC; Becker PA; Jones DR; Hall SD Clin Pharmacol Ther; 1998 Oct; 64(4):369-77. PubMed ID: 9797793 [TBL] [Abstract][Full Text] [Related]
22. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081 [TBL] [Abstract][Full Text] [Related]
23. Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. Koumaras C; Tziomalos K; Stavrinou E; Katsiki N; Athyros VG; Mikhailidis DP; Karagiannis A J Am Soc Hypertens; 2014 Feb; 8(2):74-82. PubMed ID: 24139833 [TBL] [Abstract][Full Text] [Related]
24. Comparative bioavailability of two atenolol tablet formulations in healthy male volunteers after a single dose administration. Martins ML; Pierossi MA; Moraes LA; Ribeiro W; Abbib Júnior E; Mendes GB; Poli A; De Nucci G; Muscará MN Int J Clin Pharmacol Ther; 1997 Aug; 35(8):324-8. PubMed ID: 9266287 [TBL] [Abstract][Full Text] [Related]
25. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Waldmeier F; Glaenzel U; Wirz B; Oberer L; Schmid D; Seiberling M; Valencia J; Riviere GJ; End P; Vaidyanathan S Drug Metab Dispos; 2007 Aug; 35(8):1418-28. PubMed ID: 17510248 [TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. Vaidyanathan S; Reynolds C; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP J Clin Pharmacol; 2007 Apr; 47(4):453-60. PubMed ID: 17389554 [TBL] [Abstract][Full Text] [Related]
27. An interaction study with cimetidine and the new angiotensin II antagonist valsartan. Schmidt EK; Antonin KH; Flesch G; Racine-Poon A Eur J Clin Pharmacol; 1998 Feb; 53(6):451-8. PubMed ID: 9551704 [TBL] [Abstract][Full Text] [Related]
28. Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren. Tapaninen T; Neuvonen PJ; Niemi M Eur J Clin Pharmacol; 2010 May; 66(5):497-502. PubMed ID: 20179914 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers. Reyderman L; Kosoglou T; Boutros T; Seiberling M; Statkevich P Curr Med Res Opin; 2004 Sep; 20(9):1493-500. PubMed ID: 15383199 [TBL] [Abstract][Full Text] [Related]
30. Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers. Weber C; Tam YK; Schmidtke-Schrezenmeier G; Jonkmann JH; van Brummelen P Eur J Clin Pharmacol; 1996; 51(1):87-90. PubMed ID: 8880057 [TBL] [Abstract][Full Text] [Related]
31. Effect of multiple cilostazol doses on single dose lovastatin pharmacokinetics in healthy volunteers. Bramer SL; Brisson J; Corey AE; Mallikaarjun S Clin Pharmacokinet; 1999; 37 Suppl 2():69-77. PubMed ID: 10702889 [TBL] [Abstract][Full Text] [Related]
32. Aliskiren in the management of hypertension. Barrios V; Escobar C Am J Cardiovasc Drugs; 2010; 10(6):349-58. PubMed ID: 21090828 [TBL] [Abstract][Full Text] [Related]
33. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Rogers JD; Zhao J; Liu L; Amin RD; Gagliano KD; Porras AG; Blum RA; Wilson MF; Stepanavage M; Vega JM Clin Pharmacol Ther; 1999 Oct; 66(4):358-66. PubMed ID: 10546919 [TBL] [Abstract][Full Text] [Related]
34. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Kyrklund C; Backman JT; Kivistö KT; Neuvonen M; Laitila J; Neuvonen PJ Clin Pharmacol Ther; 2001 May; 69(5):340-5. PubMed ID: 11372002 [TBL] [Abstract][Full Text] [Related]
35. Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects. Rebello S; Zhao S; Hariry S; Dahlke M; Alexander N; Vapurcuyan A; Hanna I; Jarugula V Eur J Clin Pharmacol; 2012 May; 68(5):697-708. PubMed ID: 22124880 [TBL] [Abstract][Full Text] [Related]
36. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Nussberger J; Gradman AH; Schmieder RE; Lins RL; Chiang Y; Prescott MF Int J Clin Pract; 2007 Sep; 61(9):1461-8. PubMed ID: 17590217 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic/pharmacodynamic modeling of renin biomarkers in subjects treated with the renin inhibitor aliskiren. Hong Y; Dingemanse J; Mager DE Clin Pharmacol Ther; 2008 Jul; 84(1):136-43. PubMed ID: 18288088 [TBL] [Abstract][Full Text] [Related]
38. Aliskiren for renin inhibition: a new class of antihypertensives. Van Tassell BW; Munger MA Ann Pharmacother; 2007 Mar; 41(3):456-64. PubMed ID: 17341529 [TBL] [Abstract][Full Text] [Related]
39. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Stanton A; Jensen C; Nussberger J; O'Brien E Hypertension; 2003 Dec; 42(6):1137-43. PubMed ID: 14597641 [TBL] [Abstract][Full Text] [Related]
40. Comparative pharmacokinetics of two brands of atenolol following a single oral administration. Irshaid YM; Rawashdeh NM; Awwadi FF; Kato MK Int J Clin Pharmacol Ther; 1996 Oct; 34(10):457-61. PubMed ID: 8897086 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]